Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj K, Skoromets A, Stolyarov I, Bass A, Sullivan H, et al. Neurology. 2012 Apr 3; 78(14):1069-78. Epub 2012 Mar 21. PMID: 22442431. Abstract CommentRecommendBookmarkWatch